Tao Zhang
Clinical trials sponsored by Tao Zhang, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a simple supplement boost rectal cancer treatment? Results expected Dec 2026 (estimated)
- New hope for Hard-to-Treat colorectal cancer? drug combo trial launches Results expected Jan 2027 (estimated)
- New triple therapy targets hard-to-treat liver metastases in colorectal cancer Results expected Aug 2027 (estimated)
-
New triple therapy targets hard-to-treat liver metastases in colorectal cancer
Disease control Not yet recruitingThis study tests a new combination of an antibody drug (QL1706), a targeted therapy (fruquintinib), and short-course radiotherapy against standard third-line therapy in 76 adults with colorectal cancer that has spread to the liver and cannot be removed by surgery. The goal is to …
Phase 2 • Sponsor: Tao Zhang • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Promising drug duo targets Hard-to-Treat HER2 cancers
Disease control Not yet recruitingThis study tests two drugs, zanidatamab and tislelizumab, combined with standard chemo or radiation for people with HER2-positive stomach or colorectal cancers. About 70 adults aged 18-75 will receive the treatment to see if it shrinks tumors and controls the disease. The goal is…
Phase 2 • Sponsor: Tao Zhang • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC